Диссертация (1140095), страница 11
Текст из файла (страница 11)
кандидата медицинских наук: 14.00.05 / КамаеваЭльвира Ревовна.- Уфа, 2008.- 126 с.12.Козловская, Н.Л. Генетическая тромбофилия и почки / Н.ЛКозловская, Л.А. Боброва// Клиническая нефрология.-2009.-№ 3.- С.23-34.13.Ляпина, Л.А. Теоретические и практические вопросы изученияфункционального состояния противосвертывающей системы крови. /Л.А.Ляпина, М.Е.Григорьева, Т.Ю.Оберган, Т.А. Шубина.- М.: ООО”Адвансед солюшнз”, 2012.- C43-51.14.Морозов, Ю.А.
Взаимосвязь Д-димера плазмы и объемапослеоперационной кровопотери у больных после протезирования клапановсердца / Ю.А.Морозов, М.А.Чарная, В.Г.Гладышев // Клиническая физиологиякровообращения.- 2007. — № 1. — С. 61-63.15.Полунина,О.С.Особенностидиагностикиитечениянеспецифических заболеваний легких и плевры у пожилых: автореф. дис.
...82доктора медицинских наук: 14.00.05 / Полунина Ольга Сергеевна- Волгоград,2007.- 40 с.16.Решетняк,Т.М.Мутациявгене5,10-метилентетpагидpофолатpедуктазы пpи системной кpасной волчанке иантифосфолипидном синдpоме/ Т.М.Решетняк, Л. И.Патpушев, Т.Л. Тихоноваи др// Терапевтический архив. – 2002. – Т.
74. – С. 28-32.17.Страмбовкая, Н.Н. Особенности течения острого периодаишемического инсульта у больных с первичными тромбофилиями / Н.Н.Страмбовская, Ю.А. Витковский// Актуальные вопросы регионарногоздравоохранения - информационно-аналитический сборник статей.- УланУдэ, - 2007.- С. 254 - 259.18.Трухачева,биологическихН.В.исследованияхМатематическаясстатистикаприменениемпакетавмедико-Statistica/Н.В.Трухачева–М.: ГЭОТАР- Медиа, 2012.- 384с.19.Якушева, Э.В.
Гемокоагуляционные сдвиги при хроническойобструктивной болезни легких / Э.В.Якушева, О.С.Полунина, Л.П.Воронина,Т.В. Прокофьева // Успехи современного естествознания. – 2008. – № 5. – С.160.20.Aibar, М.А.Hypercoagulability state and endotelial injury in stablechronic obstructive pulmonary disease patients. / М.А.Aibar, К.Laborda, F.Conget,R.Cornudella // An. Sist. Sanit. Navar.-2010.-Vol.
33 (1).- P. 43-50.21.Ajay, K. Singh. Role of Immunoturbidimetric plasma fibrin D- dimertest in patients with coronary artery disease as well as ischemic heart disease inemergency medicine / K. Singh Ajay [et al.].// Int J Cur Biomed Phar Res.- 2011.Vol. 1(2).- P. 31 – 33.8322.Al, Dieri R. Thrombin generation what have we learned/ Dieri R Al,B de Laat, HC Hemker // Blood Rev.- 2012 Sep.-Vol. 26(5).P. 197-203.23.Alehagen, U. Elevated D-dimer level is an independent risk factor forcardiovascular death in out-patients with symptoms compatible with heart failure/ UAlehagen, U Dahlström, TL.Lindahl //Thromb Haemost.- 2004 Dec.-Vol. 92(6).-P.1250-8.24.Alessi, MC. Production of plasminogen activator inhibitor 1 by humanadipose tissue - Possible link between visceral fat accumulation and vasculardisease. / MC Alessi, F Peiretti, P Morange [et al.] //Diabetes.- 1997.- Vol.
46(5).-P860–7.25.Bertina, R.M. Genetic approach to thrombophilia. / R.M. Bertina//Thromb Haemost.- 2001.-Vol.86.- P. 92–99.26.Bertina, RM. Mutation in blood coagulation factor V associated withresistance to activated protein C / RM Bertina, BP Koeleman, T Koster [et al.] //Nature.- 1994 May 5.-369(6475).-P.
64-7.27.Bertoletti, L. RIETE Investigators Pulmonary embolism and 3-monthoutcomes in 4036 patients with venous thromboembolism and chronic obstructivepulmonary disease: data from the RIETE registry. / L Bertoletti, S Quenet, SLaporte, [et al.] // Respir Res.- 2013 Jul 18;Vol. 14.- P. 75.28.Bezemer, ID. No association between the common MTHFR 677C->Tpolymorphism and venous thrombosis: results from the MEGA study.
/ ID Bezemer,CJ Doggen, HL Vos, FR Rosendaal.// Arch Intern Med.- 2007 Mar 12. Vol. 167(5).-P 497-501.29.Binder, BR. The plasminogen activator inhibitor "paradox" in cancer./ BR Binder, J. Mihaly // Immunol Lett.- 2008.-Vol.-118(2).- P.
116–24.8430.Booth, NA. Plasminogen activator inhibitor (PAI-1) in plasma andplatelets. / NA Booth, AJ Simpson, A Croll, [et al.] // Br J Haematol.- 1988.- Vok.70(3).- P. 327–33.31.Brogren, H. Platelets synthesize large amounts of active plasminogenactivator inhibitor 1. / H Brogren, L Karlsson, M Andersson, [et al.]// Blood.- 2004.Vol.
104(13).- P. 3943–8.32.Brogren, H. Platelets retain high levels of active plasminogen activatorinhibitor 1. / H. Brogren, K. Wallmark, J Deinum [et al.]// PLoS One.- 2011.Vol.6(11). -P. e26762.33.Buist, A. S.International variation in the prevalence of COPD (theBOLD Study): a population-based prevalence study/ A.S.
Buist, M.A.McBurnie,W.M.Vollmer [et al.]// Lancet.- 2007.- Vol. 370.-P. 741–750.34.Buyukasyk, NS. Increased blood coagulation and platelet activation inpatients with infective endocarditis and embolic events. /NS Buyukasyk, M Ileri, AAlper, [et al.]// Clin Cardiol.- 2004.-Vol 27.- P.154-158.35.Capitanio, R.E., [et al.]//J.
Biol. Chem.- 1982.- Vol 257.-P. 400.36.Carmeliet, P. Plasminogen activator inhibitor-1 gene deficient mice.II. Effects on hemostasis, thrombosis and thrombolysis. / P Carmeliet, JM Stassen,L Schoonjans [et al.]// Clinical Investigation.- 1993.-Vol. 92(6).-P. 2756–60.37.Carmeliet, P. Physiological consequences of loss of plasminogenactivator gene function in mice./ P Carmeliet [et al.]// Nature.- 1994.-Vol. 368.- P.419–424.38.Carmeliet, P. Plasminogen activator inhibitor-1 gene-deficient mice I:Generation by homologous recombination and characterization. / P Carmeliet [etal.]// Clinical Investigation.- 1993.- Vol. 92.- P. 2746–2755.8539.Castelló R., Plasminogen activator inhibitor-1 4G/5G polymorphismin breast cancer patients and its association with tissue PAI-1 levels and tumorseverity.
/ R.Castelló, F.España, C.Vázquez, [et al.]// Thromb. Res.- 2006.-Vol 117.P. 487-492.40.Cornelia, Barbu. REVIEW Inflammation in COPD: pathogenesis,local and systemic effects. / Barbu Cornelia, Mihaela Iordance, M. G. Man // RomJ Morphol Embryol.- 2011.-Vol. 52(1).
P. 21–27.41.Cushman, M. Deep vein thrombosis and pulmonary embolism in twocohorts: the longitudinal investigation of thromboembolism etiology. / M Cushman,AW Tsai, RH White [et al.]// Am J Med.- 2004.-Vol. 117(1).- P.19-25.42.Dart, A. Protein S, von Willebrand factor, and euglobulin lysis time asmarkers of coronary heart disease./ A Dart, B Sherrard, [et al.]// Ann. Intern. Med.1997.-Vol. 126 (1).-P. 89.43.De Stefano, V. Prothrombin G20210A mutant genotype is a risk factorfor cerebrovascular ischemic disease in young patients. /V De Stefano, P Chiusolo,K Paciaroni [et al.]// Blood.- 1998.-Vol. 91.- P. 3562–3565.44.Dempfle, C.E.
The fibrin assay comparison trial (FACT): Correlationof soluble fibrin assays with D-dimer. C.E.Dempfle, S.Zips, H. Ergul [et al.]// Ibid.2001.-Vol. 86.-P. 1204—1209.45.Den Heijer, M. Homocysteine, MTHFR and risk of venousthrombosis: a meta-analysis of published epidemiological studies. /M.Den Heijer,S.Lewington, R.Clarke // J Thromb Haemost.- 2005.- Vol. 3.- P. 292–299.46.Eddy, A.A. Plasminogen activator inhibitor-1 in chronic kidneydisease: evidence and mechanisms of action./ A.A.Eddy, A.B.Fogo// J.
Am. Soc.Nephrol.- 2006. Vol. 17. P. 2999–3012.8647.Egeberg,O.Inheritedantithrombindeficiencycausingthrombophilia./ O. Egeberg// Thromb Diath Haemorrh.-1965.- Vol.13.- P. 516-520.48.Eriksson, P. Allele-specffic increase in basal transcription of theplasminogen-activator inhibitor 1 gene is associated with myocardial infarction.
/P.Eriksson, B.Kallin, F.M.van Hooft [et al.]// Proc. Nat. Acad. Sci.- 1995.-Vol. 92.P. 1851-1855.49.Fay, WP. Vascular functions of the plasminogen activation system./WP.Fay, N.Garg, M.Sunkar// Arterioscler Thromb Vasc Biol.- 2007.-Vol. 27(6).-P.1231–7.50.Filippo, Luca Fimognari. Mechanisms of atherothrombosis in chronicobstructive pulmonary disease. / Filippo Luca Fimognari, Simone Scarlata, MariaElisabetta Conte, Raffaele Antonelli Incalzi.// Int J Chron Obstruct Pulmon Dis.2008.-Vol. 3(1).-P. 89–96.51.Folsom, AR.
Prospective study of fibrinolytic factors and incidentcoronary heart disease - The Atherosclerosis Risk in Communities (ARIC) Study./AR Folsom, N Aleksik, E Park, V Salomaa [et al.]// Arterioscler Thromb Vasc Biol.2001.- Vol. 21(4).- P. 611–7.52.Francis, R.B. Jr., Impaired fibrinolysis in coronary artery disease./R.B. Jr. Francis, D.Kawanishi, T.
Baruch [et al.]// Am. Heart J.- 1988.-Vol. 115.- P.776-780.53.Frosst, P. A candidate genetic risk factor for vascular disease: acommon mutation in methylenetetrahydrofolate reductase. / P.Frosst, H.J.Blom,R.Milos [et al.]// Nat Genet 10.- 1995.-Vol 10.- P. 111–113.54.Garg, N.
Plasminogen activator inhibitor-1 and Restenosis. /N Garg,WP Fay// Curr Drug Targets.- 2007.-Vol. 8(9).-P. 003–6.8755.Girolami, A. The pathogenesis of venous thromboembolism. /A.Girolami, P.Prandoni, P.Simioni [et al.]// Haematologica.- 1995.-Vol. 80(2Suppl).-P.25-35.56.Girolami A. Severe arterial cerebral thrombosis in a patient withprotein S deficiency (moderately reduced total and markedly reduced free proteinS): a family study. / A. Girolami, P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
